Home » Authors » James Etheridge

James Etheridge

Articles

ARTICLES

BioAlliance Gets Green Light For Phase II/III Transdrug Trial

Dec. 20, 2006

By James Etheridge

IntegraGen Setting Up U.S. Subsidiary For Diagnostics

Dec. 20, 2006

By James Etheridge

Trophos Announces Plans For ALS TRO19622 Phase II/III Trial

Dec. 13, 2006

By James Etheridge

Novexel Licenses Aminocandin From Indevus Pharmaceuticals

Dec. 13, 2006

By James Etheridge

Genfit To List Shares On Alternext Market In Paris

Dec. 13, 2006

By James Etheridge

Novexel Licenses Aminocandin From Indevus Pharmaceuticals

Dec. 13, 2006

By James Etheridge

Trophos Announces Plans For ALS TRO19622 Phase II/III Trial

Dec. 13, 2006

By James Etheridge

Genfit To List Shares On Alternext Market In Paris

Dec. 13, 2006

By James Etheridge

Biocortech, Servier To Work Together On CNS Disorders

Dec. 6, 2006

By James Etheridge

Biocortech, Servier To Work Together On CNS Disorders

Dec. 6, 2006

By James Etheridge

View All Articles by James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...